Clinical Trial Management - software & AI news

Daily news on software, AI, and companies shaping clinical trial management.

Showing 118 results
Press release cover image

Aug 18, 2026

Curavit Expands Clinical Research Capabilities with Acquisition of Lindus Health CRO Assets, Accelerating Global Trial Execution for Life Science Sponsors

Combined operations deliver unified U.S. and European trial delivery, faster recruitment, and expanded evidence-generation capabilities across pharma, biotech, medtech, diagnostics, and digital health.BOSTON, Aug. 18, 2026 /PRNewswire/ -- Curavit Clinical Research, an innovative clinical research organization (CRO) and Remote Clinical Site, today announced the acquisition of the CRO assets of Lindus Health. This transaction follows Lindus shifting focus to developing its own pipeline of therapeu
Press release cover image

Aug 18, 2026

Cumulus Neuroscience Announces Publication in Scientific Reports Demonstrating the NeuLogiq® Platform Is Feasible and Usable for At-Home, Multimodal Cognitive Assessment in People Living with ALS and FTD

Final results from the CNS-102 study, published in Scientific Reports, show that the at-home NeuLogiq® Platform can be deployed successfully in patients with significant motor and cognitive impairment — with 82% of ALS participants rating the platform easy to use and 75% rating their overall opinion of the technology positive or very positiveThis is the first published study to combine at-home EEG and multi-domain cognitive assessment in people living with ALS and associated forms of FTD, addres
A minimalist representation of a clinical trial vial and patient figure in a dark palette.

Aug 18, 2026

Merck and Sarah Cannon team up to boost oncology trial efficiency

The Sarah Cannon Research Institute (SCRI) has partnered with Merck & Co. to enhance the efficiency of community-based oncology trials, aiming to improve patient access and streamline drug development processes.This collaboration will utilize SCRI’s Accelero delivery model, which focuses on overcoming challenges in oncology trials by optimizing health record data transfer, expediting site start-up, and increasing enrollment. The model is designed to connect trial sponsors with SCRI's extensive n
A clinical trial document and pen on a desk in a dimly lit research office.

Aug 17, 2026

TCS Launch AgentHub to Bring AI Workers Into Pharma Clinical Trials

Tata Consultancy Services (TCS) has launched TCS ADD AgentHub, an AI platform aimed at enhancing the efficiency of pharmaceutical companies in clinical trials and drug development.The TCS ADD AgentHub acts as an intermediary AI agent layer within TCS's existing clinical research suite. It is designed to automate repetitive tasks such as data extraction and document review, allowing human teams to focus on governance and decision-making. This model, referred to as the Human + AI Operating Model,
A clinical trial vial and notebook in a dimly lit lab setting.

Aug 12, 2026

AI clinical monitoring agent can deliver up to 82 times the ROI in oncology: report

A recent analysis from the Tufts Center for the Study of Drug Development reveals that an AI clinical monitoring agent can yield an impressive return on investment (ROI) of up to 82 times in oncology trials, with potential net financial gains reaching $21 million per drug development program.The study assessed the digital trial platform Medable’s clinical monitoring agent, focusing on its expected net present value (eNPV). Findings indicated significant eNPV gains across various trial phases: ap
Press release cover image

Aug 12, 2026

Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers

Phase I trial in Germany will support treatment response monitoring for Kupando Therapeutics’ investigational immunotherapy using Latitude MRD testingAUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new collaboration regarding a Phase 1 clinical trial, sponsored by Kupando Therapeutics.Under the agreement, Natera’s Latitude tissue-free assay for molecular residual disease (MRD) detection will be used in Kupand
A minimalist representation of patient engagement in clinical trials.

Aug 5, 2026

Massive Bio makes first AI investment, backing healthcare startup Rivvi

Massive Bio has made its first investment in AI, supporting Rivvi, a startup focused on AI infrastructure for healthcare and life sciences. This partnership, revealed at the Ai4 conference in Las Vegas on August 4, 2026, aims to enhance patient engagement and clinical trial matching in oncology.The collaboration seeks to bridge the gap in therapeutic clinical trial enrollment, which currently sees only 3% to 5% of U.S. adults with cancer participating. Factors such as fragmented data and complex
Silhouette of a clinical trial participant with an AI brain icon above

Aug 4, 2026

Icon inks Anthropic partnership to deploy Claude into clinical trials

Icon has partnered with Anthropic to integrate Claude’s AI capabilities into clinical trials, aiming to enhance operational efficiency in drug development.In a significant move to bolster its digital innovation, Icon, a contract research organization, has entered a multi-year collaboration with Anthropic. This partnership will utilize Anthropic’s Life Sciences research team to enhance Icon's agentic AI platform, Orbis. The goal is to improve site intelligence and study planning through advanced
Press release cover image

Aug 4, 2026

Pathos AI Enters Collaboration and Co-Exclusive Licensing Agreement to Advance Novel ERα PROTAC for ER+ Breast Cancer into the Clinic

Pathos assumes responsibility for early clinical development of AZD4241, utilizing its AI-driven Foundry platform to drive patient stratification and trial design.NEW YORK--(BUSINESS WIRE)--Pathos AI, a clinical-stage AI and technology company advancing its own pipeline of cancer therapies, today announced a collaboration and co-exclusive licensing agreement with AstraZeneca. Under this agreement, the companies will advance AZD4241, a preclinical investigational therapy for patients with estroge
Press release cover image

Aug 4, 2026

Pathos AI Enters Global Licensing Agreement with Alphamab Oncology on JSKN016, a First-in-Class TROP2/HER3 Bispecific ADC

NEW YORK--(BUSINESS WIRE)--Pathos AI, a clinical-stage AI and technology company advancing its own pipeline of cancer therapies, today announced a licensing agreement with Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (“Alphamab”), a wholly-owned subsidiary of Alphamab Oncology (Stock Code: 9966.HK), on JSKN016, a first-in-class (FIC) TROP2/HER3 bispecific antibody-drug conjugate (ADC) independently developed by Alphamab.Pursuant to the licensing agreement, Alphamab granted Pathos an exclusive l
A clinical trial vial and syringe on a lab bench in a clinical setting.

Aug 3, 2026

Straive Named a Leader in AIM Research’s 2026 PeMa Quadrant for Life Sciences and Healthcare AI Services

Straive has achieved recognition as a Leader in AIM Research’s 2026 Penetration Maturity (PeMa) Quadrant for AI services in the life sciences and healthcare sectors.This accolade highlights Straive’s comprehensive capabilities in various critical areas, including clinical development, regulatory affairs, and pharmacovigilance. AIM Research, known for its focus on AI and data science, aims to assist enterprise buyers in evaluating technology and service providers through its PeMa Quadrants.Straiv
A minimalist illustration of a clipboard representing clinical data.

Jul 28, 2026

ICON And Anthropic Form Multi-Year Collaboration To Bring Claude AI Across Clinical Trials

ICON has partnered with Anthropic to enhance clinical trials through AI integration, focusing on improving operational efficiencies and decision-making.This collaboration aims to leverage Anthropic's Claude AI within ICON's Orbis platform, which is designed to facilitate secure AI applications across the clinical trial lifecycle. The initiative will initially target four key capabilities: site intelligence and study planning, predictive trial intelligence, protocol optimization, and seamless int